20240041906. PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS simplified abstract (The U.S.A., as Represented by the Secretary, Department of Health and Human Services)

PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS

Organization Name

The U.S.A., as Represented by the Secretary, Department of Health and Human Services

Inventor(s)

Walid Heneine of Atlanta GA (US)

Thomas M. Folks of Helotes TX (US)

Robert Janssen of Atlanta GA (US)

Ronald A. Otten of Villa Rica GA (US)

Jose Gerardo Garcia Lerma of Decatur GA (US)

PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240041906 titled 'PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS

Simplified Explanation

The abstract describes a process for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. The process involves administering a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor to the primate host prior to exposure to the retrovirus. The administration can be done in a single dose within 24 hours of exposure or through regular daily doses.

• The process involves administering a combination of two types of reverse transcriptase inhibitors to a primate host.
• The administration can be done in a single dose within 24 hours of exposure or through regular daily doses.
• The combination of inhibitors provides protection against the retrovirus becoming self-replicating after infecting the host.
• The process can also be used to control retrovirus transmission within a population by administering the combination to a high-risk subpopulation prior to sexual exposure to the retrovirus source.

Potential Applications:

• Prevention of immunodeficiency retroviral infections in primates.
• Control of retrovirus transmission within high-risk populations.

Problems Solved:

• Protection against self-replicating retroviral infections.
• Prevention of retrovirus transmission within populations.

Benefits:

• Effective protection can be achieved with a single dose or regular daily doses.
• Provides a method for controlling retrovirus transmission within high-risk populations.

Original Abstract Submitted

a process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. the administration is effective if provided in a single dose within 24 hours of the exposure. a regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. a process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.